Integrase Strand Transfer Inhibitors in HIV Therapy

por Mesplède, Thibault, Wainberg, Mark A.
Publicado 2013

Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?

por Mesplède, Thibault, Wainberg, Mark A.
Publicado 2014

Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence

por Mesplède, Thibault, Wainberg, Mark A.
Publicado 2015

Implications for the future of the HIV epidemic if drug resistance against dolutegravir cannot occur in first-line therapy

por Wainberg, Mark A, Mesplede, Thibault
Publicado 2015

Will LEDGIN molecules be able to play a role in a cure for HIV infection?

por Mesplède, Thibault, Wainberg, Mark A.
Publicado 2016

The latest evidence for possible HIV-1 curative strategies

por Pham, Hanh Thi, Mesplède, Thibault
Publicado 2018

What if HIV were unable to develop resistance against a new therapeutic agent?

por Wainberg, Mark A, Mesplède, Thibault, Raffi, Francois
Publicado 2013

Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses

por Pham, Hanh T., Mesplède, Thibault, Wainberg, Mark A.
Publicado 2016

Nonhuman Primates and Humanized Mice for Studies of HIV-1 Integrase Inhibitors: A Review

por Hassounah, Said A., Mesplède, Thibault, Wainberg, Mark A.
Publicado 2016

HIV drug resistance against strand transfer integrase inhibitors

por Anstett, Kaitlin, Brenner, Bluma, Mesplede, Thibault, Wainberg, Mark A.
Publicado 2017

A Mathematical Model to Predict HIV Virological Failure and Elucidate the Role of Lymph Node Drug Penetration

por Sanche, S, Sheehan, N, Mesplède, T, Wainberg, MA, Li, J, Nekka, F
Publicado 2017

Exploring an alternative explanation for the second phase of viral decay: Infection of short-lived cells in a drug-limited compartment during HAART

por Sanche, Steven, Mesplède, Thibault, Sheehan, Nancy L., Li, Jun, Nekka, Fahima
Publicado 2018

The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound

por Wainberg, Mark, Anstett, Kaitlin, Mesplede, Thibault, Quashie, Peter, Han, Yingshan, Oliveira, Maureen
Publicado 2014

Cenicriviroc blocks HIV entry but does not lead to redistribution of HIV into extracellular space like maraviroc

por Kramer, Victor, Hassounah, Said, Colby-Germinario, Susan, Mesplède, Thibault, Lefebvre, Eric, Wainberg, Mark
Publicado 2014

Structural Studies of the HIV-1 Integrase Protein: Compound Screening and Characterization of a DNA-Binding Inhibitor

por Quashie, Peter K., Han, Ying-Shan, Hassounah, Said, Mesplède, Thibault, Wainberg, Mark A.
Publicado 2015

Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection

por Pham, Hanh Thi, Xiao, Meng A, Principe, Miguel AV, Wong, Alexander, Mesplède, Thibault
Publicado 2020

The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness

por Wares, Melissa, Mesplède, Thibault, Quashie, Peter K, Osman, Nathan, Han, Yingshan, Wainberg, Mark A
Publicado 2014

Fitness Impaired Drug Resistant HIV-1 Is Not Compromised in Cell-to-Cell Transmission or Establishment of and Reactivation from Latency

por Bastarache, Sophie M., Mesplède, Thibault, Donahue, Daniel A., Sloan, Richard D., Wainberg, Mark A.
Publicado 2014

HIV-1 group O integrase displays lower susceptibility to raltegravir and has a different mutational pathway for resistance than HIV-1 group M

por Depatureaux, Agnès, Mesplède, Thibault, Quashie, Peter, Oliveira, Maureen, Moisi, Daniela, Brenner, Bluma, Wainberg, Mark
Publicado 2014

Automethylation of protein arginine methyltransferase 6 (PRMT6) regulates its stability and its anti-HIV-1 activity

por Singhroy, Diane N, Mesplède, Thibault, Sabbah, Arielle, Quashie, Peter K, Falgueyret, Jean-Pierre, Wainberg, Mark A
Publicado 2013